William Blair Brokers Lift Earnings Estimates for Genmab A/S

Key Points

• William Blair revised its Q3 2025 earnings estimates for Genmab A/S, increasing the expected earnings per share from $0.46 to $0.47.
• Multiple research firms, including Wall Street Zen and Zacks Research, have upgraded Genmab A/S to a "strong-buy" rating, reflecting growing confidence in the company's prospects.
• Genmab A/S has a current market capitalization of $20.42 billion, with its shares trading around $31.81, marking a 0.1% decrease on recent trading.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Analysts at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for Genmab A/S in a note issued to investors on Friday, October 10th. William Blair analyst M. Phipps now expects that the company will earn $0.47 per share for the quarter, up from their previous estimate of $0.46. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S's FY2025 earnings at $1.75 EPS.

Other research analysts have also issued reports about the company. Wall Street Zen upgraded Genmab A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 26th. Zacks Research upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 2nd. Weiss Ratings restated a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Guggenheim upgraded Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price for the company in a research note on Tuesday, September 23rd. Finally, HC Wainwright upped their target price on Genmab A/S from $36.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and a consensus target price of $40.80.

Genmab A/S Trading Down 0.1%

Shares of NASDAQ GMAB opened at $31.81 on Monday. The business has a fifty day simple moving average of $26.86 and a 200 day simple moving average of $22.91. The firm has a market capitalization of $20.42 billion, a price-to-earnings ratio of 15.98, a PEG ratio of 1.79 and a beta of 0.98. Genmab A/S has a one year low of $17.24 and a one year high of $33.63.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The company had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC boosted its holdings in Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC boosted its holdings in Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company's stock valued at $37,000 after acquiring an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after acquiring an additional 1,070 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company's stock valued at $44,000 after acquiring an additional 1,174 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.